BOM:526139 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BOM:526139 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Transgene Biotek Ltd BOM:526139
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Transgene Biotek's Enterprise Value is ₹395.80 Mil. Transgene Biotek's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.00 Mil. Therefore, Transgene Biotek's EV-to-FCF for today is .
The historical rank and industry rank for Transgene Biotek's EV-to-FCF or its related term are showing as below:
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-24), Transgene Biotek's stock price is ₹2.97. Transgene Biotek's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-0.220. Therefore, Transgene Biotek's PE Ratio (TTM) for today is At Loss.
Transgene Biotek (BOM:526139) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Transgene Biotek's PE Ratio (TTM) for today is calculated as:
| PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
| = | 2.97 | / | -0.220 | |
| = | At Loss |
Transgene Biotek's share price for today is ₹2.97.
Transgene Biotek's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-0.220.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
The historical data trend for Transgene Biotek's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| Transgene Biotek Annual Data | |||||||||||||||||||||
| Trend | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | Mar23 | Mar24 | Mar25 | Mar26 | |||||||||||
| EV-to-FCF | Get a 7-Day Free Trial |
|
|
402.31 | -24,597.02 | 16,450.02 | -78.65 | -2,838.80 | |||||||||||||
| Transgene Biotek Quarterly Data | ||||||||||||||||||||
| Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | Jun25 | Sep25 | Dec25 | Mar26 | |
| EV-to-FCF | Get a 7-Day Free Trial |
|
|
|
|
|
|
|
|
|
|
|
|
-78.65 | 0.00 | 0.00 | 0.00 | -2,838.80 | ||
For the Biotechnology subindustry, Transgene Biotek's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Transgene Biotek's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Transgene Biotek's EV-to-FCF falls into.
Transgene Biotek's EV-to-FCF for today is calculated as:
| EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
| = | 395.797 | / | 0 | |
| = |
Transgene Biotek's current Enterprise Value is ₹395.80 Mil.
Transgene Biotek's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Based on GuruFocus' analysis, Transgene Biotek stock appears to be undervalued. The current stock price of ₹2.97 is trading 55.1% below its estimated GF Value™ of ₹6.61. GuruFocus considers Transgene Biotek to be Possible Value Trap.
Key valuation signals for BOM:526139:
No single metric tells the full story. See the BOM:526139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.